Header Logo

Connection

Paul Carvey to Parkinson Disease

Back to Details
This is a "connection" page, showing publications Paul Carvey has written about Parkinson Disease.
Paul Carvey
Connection Strength
1.445
Parkinson Disease
  1. Neuroinflammation and peripheral immune infiltration in Parkinson's disease: an autoimmune hypothesis. Cell Transplant. 2008; 17(4):363-72.
    View in: PubMed
    Score: 0.159
  2. Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis. Cell Transplant. 2006; 15(3):239-50.
    View in: PubMed
    Score: 0.138
  3. Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain. Neuroscience. 2004; 124(3):619-28.
    View in: PubMed
    Score: 0.121
  4. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res Dev Brain Res. 2002 Jan 31; 133(1):27-35.
    View in: PubMed
    Score: 0.106
  5. In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov Disord. 2002 Jan; 17(1):116-24.
    View in: PubMed
    Score: 0.105
  6. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology. 1998 Feb; 50(2):515-7.
    View in: PubMed
    Score: 0.080
  7. The stability of carbidopa in solution. Mov Disord. 1997 Jul; 12(4):608-10.
    View in: PubMed
    Score: 0.077
  8. Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels. Neurology. 1996 Oct; 47(4):1037-42.
    View in: PubMed
    Score: 0.073
  9. Cerebrospinal fluid from patients with Parkinson's disease alters the survival of dopamine neurons in mesencephalic culture. Exp Neurol. 1994 Mar; 126(1):15-24.
    View in: PubMed
    Score: 0.061
  10. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Mov Disord. 2014 Jul; 29(8):999-1009.
    View in: PubMed
    Score: 0.060
  11. Striatal extracts from patients with Parkinson's disease promote dopamine neuron growth in mesencephalic cultures. Exp Neurol. 1993 Mar; 120(1):149-52.
    View in: PubMed
    Score: 0.057
  12. Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy. J Neural Transm (Vienna). 2012 Jan; 119(1):59-71.
    View in: PubMed
    Score: 0.051
  13. The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic markers in Parkinson's disease. Neurology. 1991 May; 41(5 Suppl 2):53-8; discussion 59-60.
    View in: PubMed
    Score: 0.050
  14. Disappearance of a putative DA-neuron antibody following adrenal medulla transplantation: relationship to a striatal-derived DA neuron trophic factor. Prog Brain Res. 1990; 82:693-7.
    View in: PubMed
    Score: 0.046
  15. An antibody in the CSF of Parkinson's disease patients disappears following adrenal medulla transplantation. Neurosci Lett. 1988 Nov 22; 94(1-2):192-7.
    View in: PubMed
    Score: 0.042
  16. Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007. Environ Health Perspect. 2009 Jan; 117(1):117-21.
    View in: PubMed
    Score: 0.042
  17. Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant. 2007; 16(3):285-99.
    View in: PubMed
    Score: 0.037
  18. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 May 14; 58(9):1418-22.
    View in: PubMed
    Score: 0.027
  19. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science. 2000 Oct 27; 290(5492):767-73.
    View in: PubMed
    Score: 0.024
  20. TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid. Exp Neurol. 1996 Dec; 142(2):313-22.
    View in: PubMed
    Score: 0.018
  21. Blood levodopa levels and unified Parkinson's disease rating scale function: with and without exercise. Neurology. 1993 May; 43(5):1040-2.
    View in: PubMed
    Score: 0.014
  22. Clinical improvement in parkinsonian patients undergoing adrenal to caudate transplantation is not reflected by chromogranin A or basic fibroblast growth factor in ventricular fluid. Exp Neurol. 1991 Mar; 111(3):276-81.
    View in: PubMed
    Score: 0.012
  23. Investigations on auto-antibodies in Alzheimer's and Parkinson's diseases, using defined neuronal cultures. J Neural Transm Suppl. 1990; 29:195-206.
    View in: PubMed
    Score: 0.011
  24. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations. Neurology. 1988 Jul; 38(7):1143-6.
    View in: PubMed
    Score: 0.010
  25. Altered glutathione homeostasis in animals prenatally exposed to lipopolysaccharide. Neurochem Int. 2007 Mar; 50(4):671-80.
    View in: PubMed
    Score: 0.009
  26. Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem. 2005 Jun 03; 280(22):21418-26.
    View in: PubMed
    Score: 0.008
  27. Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use. Mov Disord. 1996 Jan; 11(1):24-6.
    View in: PubMed
    Score: 0.004
  28. Drug-induced myoclonus. Adv Neurol. 1986; 43:251-64.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.